Correction: Prediction of survival prognosis of non-small cell lung cancer by APE1 through regulation of epithelial-mesenchymal transition

Xi Wei; Qing Li; Ying Li; Wei Duan; Chongbiao Huang; Xiangqian Zheng; Lei Sun; Jingtao Luo; Dong Wang; Sheng Zhang; Xiaojie Xin; Ming Gao

doi:10.18632/oncotarget.28141

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Prediction of survival prognosis of non-small cell lung cancer by APE1 through regulation of epithelial-mesenchymal transition

PDF | How to cite

Oncotarget. 2022; 13:118-119. https://doi.org/10.18632/oncotarget.28141

Metrics: PDF 1534 views | ?

Xi Wei^1,*, Qing Li^2,*, Ying Li^3,*, Wei Duan², Chongbiao Huang⁴, Xiangqian Zheng⁷, Lei Sun⁵, Jingtao Luo⁶, Dong Wang², Sheng Zhang¹, Xiaojie Xin¹ and Ming Gao⁷

¹Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
²Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, China
³The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
⁴Department of Senior Ward, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
⁵Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
⁶The Department of Otorhinolaryngology and Maxillofacial Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China
⁷Department of Thyroid and Cervical Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
^*These authors contributed equally to this work

Published: January 13, 2022

Copyright: © 2022 Wei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4D, the 3rd row, 3rd panel image is an accidental duplicate of the 1st row, 2nd panel image. In addition, the figure legend for 4D has been updated to read, ‘D. A549 cells were indicated by immunofluorescence after APE1 siRNA and inhibitor AT101 treatment. (magnification: 1000×)’. The corrected Figure 4D, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:28523–28539. DOI: https://doi.org/10.18632/oncotarget.8660

Figure 4: (D) A549 cells were indicated by immunofluorescence after APE1 siRNA and inhibitor AT101 treatment. (magnification: 1000×).

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28141

Publication Alerts

Corrections:

Correction: Prediction of survival prognosis of non-small cell lung cancer by APE1 through regulation of epithelial-mesenchymal transition